REMICADE: FDA approves Inflectra, a biosimilar to Remicade

The FDA has approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA. Inflectra is biosimilar to Janssen Biotech's Remicade (infliximab), which was originally licensed in 1998. Inflectra is approved and can be prescribed by a health care professional for the treatment of: adult patients and [...]The post FDA approves Inflectra, a biosimilar to Remicade appeared first on CenterWatch News Online.